Healthcare / Drug Manufacturers - Specialty & GenericBSEIN
$118.75
+0.95 (+0.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-3.2M · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
14.4x
↓EV/EBITDA
9.3x
↓ROE
7.7%
↑Gross Margin
32.1%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+1.3%
FCF CAGR
—
FCF margin
3.2%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.07B · net income $108.3M · FCF $34.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.07B | $1.07B | $1.07B | $1.05B | $1.03B |
| Net Income | $108.3M | $108.3M | $137.9M | $141.1M | $140.7M |
| EBITDA | $170.4M | $170.4M | $206.7M | $212.2M | $208.3M |
| EPS | 8.22 | 8.22 | 10.47 | 10.71 | 11.94 |
| Gross Margin | 32.1% | 32.1% | 35.5% | 33.6% | 35.1% |
| Operating Margin | 10.5% | 10.5% | 14.4% | 16.4% | 17.8% |
| Net Margin | 10.1% | 10.1% | 12.9% | 13.4% | 13.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 |
| Current Ratio | 3.40 | 3.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $34.0M | $34.0M | $-117.2M | $-3.2M | $-39.1M |
| Returns | |||||
| ROE | 7.7% | 7.7% | 10.3% | 11.3% | 14.6% |
| Valuation | |||||
| P/E | 14.45 | 14.45 | 13.83 | 18.99 | 18.76 |
| EV/EBITDA | 9.30 | 9.30 | 9.30 | 11.89 | 12.78 |
| P/B | 1.11 | 1.11 | 1.43 | 2.14 | 2.75 |
| Growth & Yield | |||||
| Revenue Growth | -0.4% | -0.4% | 1.9% | 2.5% | — |
| EPS Growth | -21.5% | -21.5% | -2.2% | -10.3% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.6%
EPS terminal req.
$10.54
Spread vs growth
-30.1%
5Y implied EPS CAGR
9.2%
EPS terminal req.
$12.75
Spread vs growth
-30.7%
10Y implied EPS CAGR
9.6%
EPS terminal req.
$20.53
Spread vs growth
-31.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.0%
Start / end P/E
14.7x → 14.4x
EPS bridge
10.47 → 8.22
Residual
+0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.